Home › Funds › Catalio Capital Management, LP › FDMT
Catalio Capital Management, LP position in FDMT
4D MOLECULAR THERAPEUTICS IN · Health Care
Catalio Capital Management, LP reported holding 684,753 shares of FDMT (4D MOLECULAR THERAPEUTICS IN) in its Q3 2026 13F filing — a position valued at US$9.8M, representing 1.83% of its reported portfolio and ranking #23 among its reported holdings. Catalio Capital Management, LP has disclosed FDMT holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Catalio Capital Management, LP's FDMT position evolved
Catalio Capital Management, LP first disclosed a stake in FDMT in Q2 2026 at 471,254 shares (US$6.3M). The position peaked in Q3 2026 at 684,753 shares, worth US$9.8M. Across 2 filings, Catalio Capital Management, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 684,753 shares valued at US$9.8M — an increase of 213,499 shares quarter over quarter.. Notable position changes include a 45% increase in Q3 2026 (shares fell 21% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 471.25K | $6.27M | New |
| Q3 2026 | 684.75K | $9.80M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About FDMT and 13F data
FDMT (4D MOLECULAR THERAPEUTICS IN) is a Health Care company. 30 other funds we track also report a position in FDMT — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$72.3M), Novo Holdings A/S (US$42.9M), BVF INC/IL (US$41.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding FDMT
- RA CAPITAL MANAGEMENT, L.P. 5.05M sh · $72.26M · Q3 2026
- Novo Holdings A/S 3.00M sh · $42.93M · Q3 2026
- BVF INC/IL 2.88M sh · $41.20M · Q3 2026
- Trails Edge Capital Partners, LP 2.23M sh · $31.88M · Q3 2026
- ARMISTICE CAPITAL, LLC 1.95M sh · $27.90M · Q3 2026
- Evergreen Quality Fund GP, Ltd. 951.47K sh · $13.62M · Q3 2026
- Parkman Healthcare Partners LLC 772.18K sh · $11.05M · Q3 2026
- ACUTA CAPITAL PARTNERS, LLC 535.11K sh · $7.66M · Q3 2026
- DIADEMA PARTNERS LP 421.11K sh · $6.03M · Q3 2026
More on Catalio Capital Management, LP
FAQ
How long has Catalio Capital Management, LP held FDMT?
Catalio Capital Management, LP has disclosed FDMT holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Catalio Capital Management, LP's current position in FDMT?
As of Q3 2026, Catalio Capital Management, LP holds 684.75K shares of FDMT (4D MOLECULAR THERAPEUTICS IN), valued at $9.80M, representing 1.83% of its reported portfolio and ranking #23.
Has Catalio Capital Management, LP been buying or selling FDMT?
In the latest 13F filing (Q3 2026), Catalio Capital Management, LP increased its position in FDMT. The position peaked in Q3 2026 at 684.75K shares.
Which other funds hold FDMT?
Other major institutional holders of FDMT include RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, BVF INC/IL, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.